



Formulation & Regulatory Dossier

CP Oat Avenanthramide Extract

Standardized oat avenanthramides (AV-A, AV-B, AV-C), 100–120 ppm

Product No. 902-3043 · Oat extract CAS 84012-26-0 · EINECS 281-672-4

A consolidated technical, clinical, and global regulatory reference
prepared for prospective formulation partners

Ceapro Inc. — a subsidiary of COSCIENS Biopharma

7824 – 51 Avenue NW, Edmonton, Alberta, Canada T6E 6W2

Issued August 2026 · Confidential — for business-to-business use

Table of Contents

1. Executive Summary	3
2. About the Manufacturer	3
3. Ingredient Identification & Composition	4
4. Technical Specifications	5
5. Formulation Guidance	6
6. Clinical & Scientific Evidence	7
7. Positioning: The Avenanthramide Advantage.....	9
8. Regulatory & Compliance	10
9. Safety Summary (SDS).....	11
10. Handling, Storage & Supply	12
11. Sales & Technical Inquiries	12
Appendix A. Source Document Register	12

1. Executive Summary

Avenanthramides are a group of naturally occurring phenolic compounds found **exclusively in oats** (*Avena sativa*). CP Oat Avenanthramide Extract is scientifically standardized to deliver high-purity avenanthramides (AV-A, AV-B, AV-C) at 100–120 ppm through Ceapro's patented process. Supplied as a pale-yellow-to-brown glycerol/water solution, it provides powerful anti-itch, anti-irritant, anti-redness, and antioxidant benefits — a gentle yet highly effective soothing active suitable even for sensitive populations, including children and reactive skin.

This dossier consolidates everything a formulation partner needs to evaluate, specify, and integrate the ingredient: full identification and composition, technical specifications with a representative certificate of analysis, practical formulation guidance, the clinical and mechanistic evidence base, positioning around the avenanthramide advantage, and a complete regulatory and compliance package spanning REACH scope, ISO 16128 naturalness, California SB 484/SB 312, safety classification, and Ceapro's battery of product declarations.

At a glance

Attribute	Summary
Ingredient / INCI	CP Oat Avenanthramide Extract — <i>Avena Sativa (Oat) Kernel Extract, Glycerin, Aqua, Potassium Sorbate</i>
Active	Standardized oat avenanthramides AV-A, AV-B, AV-C at 100–120 ppm
Base / carrier	Glycerol and water (1:1 w/w)
Form	Clear-to-hazy, pale-yellow-to-brown solution; natural low oat odour
Recommended use level	0.5–5.0%
Formulating pH / temperature	pH 2–8 · 25–50 °C
Solubility	Water-soluble; aqueous, aqueous/alcohol, and emulsion systems
Preservation	Potassium sorbate 0.2% (w/w)
Safety (GHS/CLP)	Not classified as hazardous; not a dangerous good for transport
Positioning	Oat-exclusive, standardized soothing/anti-irritant active for sensitive skin
Certifications	Ecocert natural registration, ISO 16128 natural origin 98.99%, Non-GMO, not animal-tested
Shelf life	12 months unopened; store cool/dry, protect from light

2. About the Manufacturer

Established in 1994, **Ceapro Inc.** is a Canadian biotechnology company recognized for premium, science-backed natural oat-derived ingredients. Ceapro operates a 30,000 sq. ft. GMP bio-processing facility in Edmonton, Alberta, offering integrated R&D, pilot-scale, and commercial production. The company is a subsidiary of COSCIENS Biopharma.

Ceapro's actives are manufactured under a quality management system aligned with **ISO 9001:2015**, and **EFfCI** good-manufacturing-practice frameworks. Proprietary green-processing technologies — ethanol fractionation, scalable chromatography, and Pressurized Gas Expanded (PGX) drying — allow Ceapro to concentrate oat bioactives into high-purity, consistent ingredients. Oats are sustainably grown in North America (the world's second-largest oat-producing region), supporting stable supply, competitive pricing, and full field-to-extract traceability.

Trusted oat expertise

Oat actives supplied to numerous global personal-care brands for 30+ years.

Multidisciplinary team: natural-product chemistry, microbiology, biochemistry, immunology, and chemical process engineering.

One-stop portfolio of oat-based actives and delivery systems, with R&D and QA support and fully customized formula solutions.

3. Ingredient Identification & Composition

3.1 Identification

Parameter	Value
Trade name	CP Oat Avenanthramide Extract
Ceapro product number	902-3043
INCI names	<i>Avena Sativa (Oat) Kernel Extract, Glycerin, Aqua (Water), Potassium Sorbate</i>
Active compounds	Avenanthramides AV-A, AV-B, AV-C (oat phenolic amides)
Standardization	100–120 ppm total avenanthramides (0.010–0.012%)
Oat extract CAS / EC	84012-26-0 / 281-672-4
Botanical source	<i>Avena sativa</i> (oat grain), non-GMO
Carrier	Glycerol and water (1:1 w/w)
Country of manufacture	Canada
Manufacturing platform	Patented process, composition, and methods of use; not chemically modified

Avenanthramides are unique to oats: a family of 20–30 naturally occurring polyphenols recognized as among the most soothing components in the grain. Standardizing to a defined AV-A/AV-B/AV-C level gives formulators consistent, quantifiable actives batch to batch.

3.2 Full Composition

The extract is delivered in a glycerol/water carrier with a single food-grade preservative:

Component (INCI / function)	CAS No.	EC / EINECS	Nominal %
Glycerin — carrier / humectant	56-81-5	200-289-5	≤ 50 (1:1 with water)
Aqua (Water) — carrier	7732-18-5	231-791-2	≤ 50 (1:1 with glycerin)
<i>Avena Sativa (Oat) Kernel Extract</i> — active	84012-26-0	281-672-4	0.010–0.012 (100–120 ppm AVA)
Potassium Sorbate — preservative	590-00-1	246-376-1	0.20–0.25

Active chemistry: avenanthramides are low-molecular-weight phenolic amides (anthranilic-acid derivatives) with well-documented anti-inflammatory and antioxidant activity.

Note on glycerin: the glycerin carrier is palm-derived from RSPO-certified sources.

4. Technical Specifications

4.1 Physical & Organoleptic Properties

Property	Specification	Method
Colour	Pale yellow – brown	Visual
Appearance	Clear – hazy liquid	Visual
Odour	Natural low oat odour (Ceapro reference standard)	Sensory
Avenanthramides (AV-A, AV-B, AV-C)	100 – 120 ppm	Internal
Protein	≤ 2.0 %	Kjeldahl (AOAC)
pH @ 25 °C	3.50 – 5.00	—
Turbidity @ 25 °C	< 20 NTU	Nephelometry (EPA 180.1)
Residual solvent (ethanol)	≤ 2.5 %	Megazyme AOAC 2019.08
Base / carrier	Glycerol : water (1:1 w/w)	—

4.2 Microbiological Specifications

Parameter	Specification	Method
Aerobic plate count	Max 100 cfu/mL	MFHPB-18
Yeasts & moulds	Max 10 cfu/mL	MFHPB-22
Gram-negative bacteria (<i>E. coli</i> , <i>P. aeruginosa</i> , <i>Salmonella spp.</i>)	Absent	MFHPB-34 / MFLP-29
<i>Staphylococcus aureus</i>	Absent	MFHPB-21

Preservative system

The product is preserved with 0.2% (w/w) potassium sorbate. Sorbate efficacy is pH-dependent; the native pH of 3.5–5.0 keeps it within its effective range. The glycerol-rich carrier also lowers water activity, further supporting stability.

4.3 Impurity & Heavy-Metal Profile

Residual solvent and glycol impurities are tested routinely; heavy metals are tested periodically per Ceapro's general impurities protocol. Typical control limits:

Analyte	Limit	Method
Residual solvent (ethanol)	≤ 2.5 %	Megazyme
Diethylene glycol	≤ 0.1 %	GC-FID
Ethylene glycol	≤ 0.1 %	GC-FID
Arsenic / Cadmium / Lead / Mercury / Antimony	As < 0.03 ppm; others < 0.02 ppm	ICP-MS

4.4 Representative Certificate of Analysis

Representative results from production lot **ED26C3** (manufactured March 2026; expiry March 2027) illustrate typical performance well within specification:

Parameter	Specification	Result (Lot ED26C3)
Colour	Pale yellow – brown	Brown
Appearance	Clear – hazy liquid	Hazy
Odour	Ceapro reference standard	Pass
Avenanthramides (AV-A/B/C)	100.0–120.0 ppm	119.6 ppm
Protein	< 2.00 %	0.90 %
Turbidity @ 25 °C	< 20.00 NTU	11.91 NTU
pH @ 25 °C	3.50–5.00	4.37
Residual solvent (ethanol)	≤ 2.5 %	1.7 %
Diethylene / ethylene glycol	≤ 0.10 % each	< 0.10 %
Aerobic plate count	Max 100 cfu/mL	< 1
Yeasts & moulds	Max 10 cfu/mL	< 5
Pathogens (Gram-neg / <i>S. aureus</i> / rods)	Absent	Absent

A current lot-specific Certificate of Analysis accompanies every shipment. Values above are representative and not a guarantee of any specific lot.

5. Formulation Guidance

5.1 Key Formulating Parameters

Parameter	Guidance
Recommended use level	0.5 – 5.0% (as supplied). Typical soothing leave-on: 1–3%; higher within range for sensitive/after-sun claims support.
Formulating pH range	2 – 8 (native pH 3.5–5.0)
Formulating temperature range	25 – 50 °C
Solubility	Water-soluble; aqueous, aqueous/alcohol, and emulsion (o/w) systems
Incorporation phase	Add to the water phase; keep containers closed when not in use
Light sensitivity	Protect from light and heat; the phenolic actives are light-sensitive

5.2 Incorporation & Compatibility

- **Add to the water (aqueous) phase.** The extract is a stable glycerol/water solution and disperses readily. Add during the cool-down phase (below ~50 °C) to limit thermal exposure of the phenolic actives.
- **Protect from light and excess heat.** Avenanthramides are phenolic and light-sensitive; opaque or UV-protective packaging helps preserve actives and colour in the finished product.
- **Broad system compatibility.** Suitable for aqueous gels, serums, aqueous/alcohol systems, and o/w emulsions across a wide pH band (2–8).
- **Pairing.** A natural soothing/anti-irritant partner to oat β -glucan, colloidal oat, panthenol, niacinamide, allantoin, and bisabolol; a useful comfort adjunct in retinoid, exfoliating-acid, and post-procedure regimens to improve tolerance.
- **Glycerin contribution.** The 1:1 glycerol/water carrier adds humectancy; account for its glycerin load (up to ~50% of the raw material) when balancing total humectant and skin-feel.

- **Avoid strong oxidizers and strong mineral acids** (e.g., sulfuric or nitric acid) in concentrated form, per the SDS incompatibility list.
- **Preservation.** The ingredient contains 0.2% potassium sorbate, but the finished product's total preservation must be independently validated for the target format and pH.

5.3 Suitable Applications

Category	Representative formats
Dermocosmetics & sensitive skincare	Soothing serums, calming moisturizers, redness-relief and post-treatment care, eye care, masks, baby/sensitive ranges
After-sun & recovery	After-sun lotions/gels, post-exposure and post-procedure soothing care
Scalp & hair care	Anti-itch and scalp-soothing shampoos, conditioners, leave-in treatments
Grooming / specialty	Post-shave and post-wax calming products, specialty comfort formats
Formulator's note Avenanthramides give a formulation a genuinely oat-signature, standardized soothing active — measurable AV-A/AV-B/AV-C content rather than a generic “oat extract.” Their anti-itch/anti-redness profile makes them especially valuable in sensitive-skin, after-sun, and “tolerance-boosting” claims.	

6. Clinical & Scientific Evidence

Avenanthramides are among the most-studied soothing components of oats, with a mechanism-of-action and human-data base spanning dermatology and inflammation research. The evidence below is provided to support formulation decision-making; finished-product claims remain the responsibility of the brand owner (see Section 10).

6.1 Mechanism & Benefit Profile

Benefit	Mechanism / basis
Anti-inflammatory / calming	Recognized as one of the most soothing components in oats; helps quiet key inflammatory signals (e.g., NF-κB / cytokine pathways) so skin feels more comfortable and less reactive.
Anti-itch (anti-pruritic)	Shown to help calm signs of itch and discomfort, easing sensations associated with stressed or reactive skin.
Anti-redness	Helps visibly reduce signs of redness and irritation by quieting the drivers of skin reactivity.
Antioxidant protection	Naturally rich in antioxidants that help defend skin against everyday environmental stressors and limit oxidative stress.
Barrier & recovery support	Supports the skin's natural barrier and resilience; useful in post-stress, post-treatment, and after-sun recovery contexts.

6.2 Benefit-Support Strength (Personal Care)

Relative strength of evidence for avenanthramides across common claim areas, as summarized in Ceapro's 2026 Product Overview:

Benefit area	Support level
Reduce inflammation, swelling & itching	★★★ Strong clinical / OTC support

Benefit area	Support level
Redness reduction (more even tone)	★★★ Strong clinical / OTC support
Antioxidant support (limits lipid peroxidation)	★★★ Strong clinical / OTC support
UV / environmental-stress support (not SPF)	★★ Supportive / adjunct
Barrier booster (repair / protection)	★ Limited / early data

Legend: ★★★ strong clinical/OTC support · ★★ supportive/adjunct · ★ limited/early data. Key sources include eCFR 21 CFR 347 (colloidal-oatmeal OTC skin protectant) and Sur et al., Arch Dermatol Res 2008 (avenanthramide anti-inflammatory / anti-itch).

6.3 Evidence Base — Selected References

The literature below is grouped by benefit area and, where reported, notes the **avenanthramide concentration and study design** so formulators can relate published effects to finished-product dosing (see §6.4). Secondary citations from a review are marked accordingly.

Anti-inflammatory & anti-itch mechanism (key study)

- **Sur et al. (2008)**, *Archives of Dermatological Research* 300(10):569–574 — avenanthramides inhibited NF-κB activation (IκB-α degradation) in keratinocytes at concentrations as low as 1 ppb and reduced IL-8 release; applied topically at 1–3 ppm, they mitigated contact hypersensitivity and neurogenic inflammation and reduced pruritogen-induced scratching in murine models. The foundational anti-inflammatory / anti-itch reference.
- **Kim & Han (2024)**, *Cosmetics* (Itch-Relieving Cosmetics review) — avenanthramides (present in oats up to ~300 ppm) block IL-8, NF-κB, and TNF-α and are structurally similar to the antihistamine tranilast, supporting anti-itch activity at low topical concentrations.

Skin-barrier support

- **Dihydroavenanthramide D** — shown to enhance skin-barrier function through upregulation of epidermal tight-junction expression (2024), supporting avenanthramides' barrier and comfort claims.

Clinical evidence — sensitive & inflamed skin

- **Theunis et al. (2017)** — randomized controlled trial, n = 30 elderly patients with chronic pruritus; a topical avenanthramide-containing oat-extract emollient improved itch over 2 weeks (as reviewed in Kim & Han 2024).
- **Grimalt et al. (2006)** — n = 173 infants with atopic dermatitis; an avenanthramide-containing oat-extract emollient applied twice daily for 6 weeks reduced topical-corticosteroid needs (as reviewed in Kim & Han 2024).
- Open-label study of an OTC oat-flour / oat-oil / oat-extract lotion with avenanthramides in sensitive skin and psoriasis (JDD); peer-reviewed oat-extract skin-tone / post-inflammatory endpoints (JAAD).

Systemic anti-inflammatory & pharmacokinetics (human)

- Avenanthramides for exercise-induced inflammation — double-blind RCT (J Int Soc Sports Nutr, 10.1186/s12970-020-00368-3); AVA-enriched oats for systemic inflammation — pilot RCT (NCT01527604; USDA-ARS).
- Avenanthramide bioavailability & pharmacokinetics — informs dose setting (J Nutr; NCT01055717; NCT02415374); COSCIENS Phase 1 results supporting a Phase 2a anti-inflammatory program.

6.4 Recommended Use Levels & Dosing Context

Ceapro's recommended use level for CP Oat Avenanthramide Extract is **0.5–5.0% of the finished formula (as supplied)**. Because the extract is standardized to 100–120 ppm avenanthramides, this delivers roughly **0.5–6 ppm avenanthramides** in the finished product — squarely in the 1–3 ppm topical range that Sur et al. (2008) found effective for anti-inflammatory and anti-itch endpoints. Dosing at ~1–3% is a reasonable starting point for soothing claims; confirm in your own system.

Note: avenanthramide levels in the literature are typically reported as active AVA (ppb–ppm). Ceapro's extract is standardized to 100–120 ppm AVA, so the as-supplied 0.5–5% guidance already brackets the effective topical range; validate stability (protect from light) and preservation in the finished format.

A complete, hyperlinked reference list for avenanthramides (and Ceapro's wider oat-actives portfolio) is available on request; see the 2026 Personal Care Product Overview.

7. Positioning: The Avenanthramide Advantage

Soothing claims are crowded, but most rely on generic botanicals or single-function agents. CP Oat Avenanthramide Extract offers something a commodity soothing ingredient cannot: an **oat-exclusive, standardized, multi-benefit active** with a real human-evidence base and clean-label credentials.

Differentiator	What it means for the brand
Oat-exclusive	Avenanthramides occur only in oats — a genuinely distinctive, story-rich active that ties directly to the trusted oat/colloidal-oatmeal heritage.
Standardized actives	Quantified to 100–120 ppm AV-A/AV-B/AV-C by HPLC, so soothing performance is consistent batch to batch — not a variable “oat extract.”
Multi-benefit	One active covers anti-itch, anti-redness, anti-inflammatory, and antioxidant claims, simplifying formulas and label stories.
Gentle enough for sensitive users	Suitable for reactive skin and sensitive populations, including children; supports “tolerance” and post-procedure positioning.
Clean & natural	Ecocert natural registration; ISO 16128 natural-origin content of 98.99%; non-GMO; not animal-tested.
Portfolio synergy	Pairs with Ceapro oat β -glucan (hydration/barrier) and oat oil (lipid/ceramide support) for a complete oat-actives system.
Positioning takeaway Where colloidal oatmeal delivers broad, monograph-recognized soothing, standardized avenanthramides let a brand make a precise, ingredient-led calming claim — and combine with oat β -glucan to tell a single “calm + hydrate” oat story that competitors sourcing commodity actives cannot easily match.	

8. Regulatory & Compliance

The following reflects Ceapro's declarations as supplied. Statements are provided in good faith for information; they do not constitute a legal guarantee of compliance in every jurisdiction, and finished-product clearance remains the brand owner's responsibility (Section 10).

8.1 REACH & Chemical-Inventory Status

REACH (EC 1907/2006): CP Oat Avenanthramide Extract is currently out-of-scope for registration. Naturally sourced extracts that do not undergo chemical change are exempt under Article 2.7(b) / Annex V (paragraph 7); in addition, Ceapro ships substances below the one-tonne-per-year threshold, so no (pre-)registration is currently required. The SDS confirms no Annex XVII restrictions and no REACH candidate (SVHC) substance.

Chemical inventories: the primary botanical is *Avena Sativa (Oat) Kernel Extract* (CAS 84012-26-0; EC 281-672-4) — the same naturally-derived oat extract that is listed or exempt across major global inventories (Canada DSL, US TSCA, EU

REACH, China IECSC, Japan ENCS, Korea KECI, Australia AIIC). A product-specific Global Regulatory Compliance statement is available from Ceapro on request.

8.2 Naturalness, California & Palm Status

Framework	Status
Ecocert	Ecocert natural registration (as noted on the Technical Data Sheet).
ISO 16128 naturalness	Natural-origin content 98.99%; natural content 98.99% (worst-case formulation basis) — predominantly of natural origin.
California SB 484 (Safe Cosmetics Act)	No intentionally added ingredients on the CSCP reportable list; no reporting obligation triggered.
California SB 312 (Fragrance/Flavor Right to Know)	No intentionally added fragrance/flavour ingredients or reportable fragrance allergens.
Palm / RSPO	Glycerin carrier is palm-derived from RSPO-certified sources. No other palm-derived ingredients.

8.3 Compliance Declarations on File

Ceapro supplies a set of signed declarations covering the ingredient and are available on request:

Declaration	Summary of statement
Composition & Non-GMO	Full quantitative composition; all ingredients non-GMO (oat extract 0.01–0.012%; glycerin:water 1:1 ≤50%; potassium sorbate 0.2–0.25%).
Country of Origin	Manufactured in Canada by Ceapro Inc.
REACH	Out-of-scope; natural-extract exemption; below one-tonne threshold.
ISO 16128 naturalness	Natural-origin and natural content 98.99%.
California SB 484 & SB 312	No reportable ingredients; no reportable fragrance allergens.
Palm status	Palm-derived glycerin from RSPO-certified source; product CoC certification in progress.
Microplastics & nanomaterials	No intentionally added microplastics (EU 2023/2055); no nanomaterials (1223/2009).
Animal testing	No animal testing of formulations (76/768/EC).
BSE / TSE	No materials of human or animal origin; no BSE/TSE risk substances (general declaration).
CMR	No carcinogenic, mutagenic, or reprotoxic substances (general declaration).
Allergen (cosmetic & food)	EU Annex III fragrance allergens not intentionally used (general declaration).
Heavy metals & impurities	As/Cd/Pb/Hg/Sb limits; glycols and ethanol controlled (general declaration; see 4.3).
PFAS / Mineral oil / Latex-paraben-free	None intentionally added at any manufacturing step (general declarations).
Gluten-free	Gluten ≤ 10 ppm (general declaration).
Halal / Vegan	Halal principles met; vegan (general declarations).
Prop 65	No listed Proposition 65 chemicals (general declaration).
GMP	ISO 9001:2015 / EFfCI aligned QMS and GMP.

9. Safety Summary (SDS)

Summarized from the product Safety Data Sheet (v2.3, 27 June 2024), prepared per Regulation (EC) No. 453/2010 / 1272/2008 (CLP) and OSHA 29 CFR 1910.1200. The SDS is the controlling document; consult it in full before handling.

9.1 Hazard Classification

GHS / CLP classification: Not classified

The product is **not classified as a hazardous substance** under Regulation (EC) No. 1272/2008 (CLP) or OSHA HazCom. No signal word, hazard statements, or precautionary pictograms apply.

Not expected to present a significant ingestion, skin, or inhalation hazard under normal conditions of use.

Direct eye contact may cause transient discomfort; avoid contact with eyes.

9.2 Handling, Reactivity & Transport

Topic	Summary
Stability	Stable under normal conditions of use.
Incompatibilities	Oxidizing agents; sulfuric acid; nitric acid; oxygen.
First aid	Skin/hair: wash with water & soap. Eyes: rinse 15 min with running water. Seek attention if irritation persists.
Transport (ADR/RID/IMDG/IATA)	Not a dangerous good; no UN number, hazard class, or packing group.
Physical state	Liquid; clear to hazy; yellow-amber; pH 3.5–5.0; soluble in water.
REACH	No Annex XVII restrictions; contains no REACH candidate (SVHC) substance.
Handling / storage	Non-hazardous material. Store cool and dry, protect from light and heat; keep containers closed when not in use.

10. Handling, Storage & Supply

Parameter	Detail
Storage	Store at room temperature in a cool, dry place; protect from light and heat. Keep unused portion sealed in the original container.
Handling	Non-hazardous material. Keep containers closed when not in use.
Shelf life	12 months in unopened containers.
Pack sizes	5 kg, 20 kg, 200 kg
Light sensitivity	Phenolic actives are light-sensitive; opaque/UV-protective packaging recommended for finished products.

10.1 Regulatory & Claims Notice

Ceapro supplies ingredients, not finished consumer products. This dossier provides general technical, clinical, and regulatory information about an oat-derived ingredient and is not medical advice. Any benefits, claims, or impressions described are for concept illustration only.

The finished-product marketer is responsible for determining appropriate claims, substantiating them with adequate evidence, and ensuring that all packaging, advertising, and communications comply with applicable

laws and guidance in the country of sale. Where claims are permitted only under specific conditions (e.g., a qualifying dose, format, or wording), those conditions must be met in the finished product.

Nothing herein is intended to diagnose, treat, cure, or prevent any disease. Final labeling, claims, and regulatory clearances remain the responsibility of the brand owner. Ceapro recommends regulatory and legal review prior to use of any claim language in market. Statements are provided in good faith and, to the best of Ceapro's knowledge, are true and correct, without warranty; purchasers should conduct their own tests to determine suitability for their intended application.

11. Sales & Technical Inquiries

Ceapro welcomes inquiries from brands, formulators, manufacturers, and development partners. Our team can help select and integrate the most appropriate oat active for your formulation, and can provide samples, current lot documentation, and formulation support.

Contact	Detail
Company	Ceapro Inc. — a subsidiary of COSCIENS Biopharma
Address	7824 – 51 Avenue NW, Edmonton, Alberta, Canada T6E 6W2
Phone	+1 (780) 421-4555
Email	info@ceapro.com
Web	ceapro.com

Appendix A. Source Document Register

This dossier consolidates the following Ceapro source documents. Current, signed/lot-specific versions are available on request and control over any summary herein.

Document	Type
CP Oat Avenanthramide Extract — Specification Sheet	Technical
CP Oat Avenanthramide Extract — Technical Data Sheet (TDS)	Technical
CP Oat Avenanthramide Extract — Certificate of Analysis (Lot ED26C3)	Quality
CP Oat Avenanthramide Extract — Safety Data Sheet (v2.3)	Safety
CP Oat Avenanthramide Extract — Composition & Non-GMO Statements	Regulatory
CP Oat Avenanthramide Extract — Country of Origin	Regulatory
CP Oat Avenanthramide Extract — REACH Statement	Regulatory
CP Oat Avenanthramide Extract — ISO 16128 Naturalness Statement	Regulatory
CP Oat Avenanthramide Extract — California SB 484 & SB 312 Compliance	Regulatory
CP Oat Avenanthramide Extract — Palm Status 2026	Regulatory
CP Oat Avenanthramide Extract — Microplastics & Nanomaterials Statement	Regulatory
CP Oat Avenanthramide Extract — Animal Testing Declaration	Regulatory
CP Oat Avenanthramide Extract — Manufacturing Flow Chart	Technical (confidential)

Document	Type
Ceapro general declarations (allergen, BSE/TSE, CMR, gluten, halal, heavy metals, latex/paraben-free, mineral oil, PFAS, Prop 65, vegan, GMP, RSPO, Whole Foods clean standards)	Regulatory
Ceapro 2026 Personal Care Product Overview (clinical evidence & references)	Marketing / Scientific

Ceapro Inc. · Nature Enhancing Life® · Edmonton, Alberta, Canada